Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: A systematic review

BMJ Supportive and Palliative Care

Volumn 7, Issue 3, 2017, Pages 230-237

  Zacho, Helle D ^a,b   Karthigaseu, Nita N ^a   Fonager, Randi F ^a   Petersen, Lars J ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

BONE TUMOR; HUMAN; INTRACTABLE PAIN; LUNG TUMOR; PAIN MEASUREMENT; PALLIATIVE THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

BONE NEOPLASMS; HUMANS; LUNG NEOPLASMS; PAIN MEASUREMENT; PAIN, INTRACTABLE; PALLIATIVE CARE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85037032285     PISSN: 2045435X     EISSN: 20454368     Source Type: Journal    
DOI: 10.1136/bmjspcare-2015-000957     Document Type: Review

References (31)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s-9s.
2. Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014;25(Suppl 3):Iii124-37.
3. Porter AT, Mcewan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
4. Oosterhof GO, Roberts JT, De Reijke TM, et al. Strontium (89) chloride vs palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44: 519-26.
5. Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett 2012;323:135-46.
6. Brady D, Parker CC, O'sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J 2013;19:71-8.
7. Christensen MH, Petersen LJ. Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review. Cancer Treat Rev 2012;38:164-71.
8. Heidenreich A, Bastian PJ, Bellmunt J, et al. Eau guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79.
9. Mohler J, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012 featured update to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:1081-7.
10. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15:738-46.
11. Shapiro D, Tareen B. Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther 2012;12:951-64.
12. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
13. Roque IF, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011;(7):CD003347.
14. Montesano T, Giacomobono S, Acqualagna G, et al. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A Retrospective Study. Clin Ter 2009;160:193-9.
15. Fan Y-X, Luo R-C, Li G-P, et al. Antalgic effects of strontium-89 therapy on bone metastases in 65 patients with lung cancer. Chin J Clin Rehabil 2004;8:812-13.
16. Zheng H, Luo RC, Fan YX. Therapeutic effects of strontium-89 against osseous metastases of lung cancer: analysis of 126 cases. Di Yi Jun Yi Da Xue Xue Bao 2004;24:1194-6.
17. Dong Z, Qing Y, Wang X. Clinical observation of internal radiotherapy using 89sr 99tc-Mdp and zoledronic acid in the treatment and pain relief of lung cancer patients with bone metastasis. Chin L Clin Oncol 2012;39:1660-2.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
19. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the consort pro extension. JAMA 2013;309:814-22.
20. Moher D, Hopewell S, Schulz KF, et al. Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10:28-55.
21. Von EE, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (Strobe) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495-9.
22. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26:2-7.
23. Su J, You C, Cai S, et al. 89srcl2, And/Or Bonefos in the treatment of bone metastasis from pulmonary carcinoma. Chin J Lung Cancer 2002;5:357-9.
24. Leondi AH, Souvatzoglou MA, Rapti AS, et al. Palliative treatment of painful disseminated bone metastases with 186Rhenium-hedp in patients with lung cancer. Q J Nucl Med Mol Imaging 2004;48:211-19.
25. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25: 1362-7.
26. Lou C, Zhang D, Yu L. [Internal strontium-89 radiotherapy for malignant bony metastasis]. Zhonghua Zhong Liu Za Zhi 2001;23:507-9.
27. Minutoli F, Herberg A, Spadaro P, et al. 186re]Hedp in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 2006;50:355-62.
28. Ratsimanohatra H, Barlesi F, Doddoli C, et al. Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer. Rev Mal Respir 2005;22(2 Pt 1):317-20.
29. Han SH, De Klerk JM, Tan S, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43:1150-6.
30. Lawrentschuk N, Davis ID, Bolton DM, et al. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol 2007;14:89-95.
31. Tian J, Cao L, Zhang J, et al. Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases. Chin Med J (Engl) 2002;115:824-8.